USP17L6P: A Potential Drug Target and Biomarker (G391622)
USP17L6P: A Potential Drug Target and Biomarker
Uncovering new drug targets and biomarkers is a critical aspect of drug development. drug targets are molecules that are associated with diseases and their treatments, while biomarkers are indicators of the disease that can be measured and analyzed. In this article, we will discuss USP17L6P, a gene that is part of the ubiquitin specific peptidase 17 like family member 6 (USP17L6P) gene. We will explore its potential as a drug target and biomarker.
USP17L6P gene and its function
The USP17L6P gene is a member of the ubiquitin specific peptidase 17 like family, which is a group of enzymes that remove specific peptides from the ubiquitin protein. This family of enzymes plays a crucial role in the regulation of protein-protein interactions, which are critical for various cellular processes.
USP17L6P is a pseudogene, which means that it is a genetic variation of a gene that has been preserved in the genome. This variation has the potential to produce a protein that differs from the wild-type gene, but has the same overall sequence.
Expression of USP17L6P in the body
USP17L6P is expressed in various tissues and cells in the body, including the liver, pancreas, and blood cells. It is primarily expressed in the liver, where it is involved in the detoxification of harmful substances.
USP17L6P and its potential as a drug target
Drug targets are molecules that are associated with diseases and their treatments. They are the focus of drug development, and are used to treat various diseases, including cancer, diabetes, and neurodegenerative disorders.
USP17L6P has been identified as a potential drug target due to its involvement in the regulation of protein-protein interactions. Many diseases are caused by the mis regulation of protein interactions, which can lead to the formation of harmful aggregates that contribute to the development of diseases.
USP17L6P has been shown to play a role in the regulation of protein-protein interactions in various cellular processes. For example, it has been shown to be involved in the regulation of the interaction between the protein PDGF-伪 and its receptor PDGF-尾.
Additionally, USP17L6P has been shown to play a role in the regulation of the interaction between the protein T-cell antigen 4 (TAG-4) and its receptor PDGFR-尾. This interaction is critical for the regulation of T-cell development and function.
USP17L6P as a biomarker
Biomarkers are indicators of the disease that can be measured and analyzed. They are used to monitor the progression of the disease and to assess the effectiveness of treatments.
USP17L6P has the potential to serve as a biomarker for various diseases, including cancer and neurodegenerative disorders. For example, USP17L6P has been shown to be involved in the regulation of protein-protein interactions in various cellular processes, which may be relevant to the regulation of cancer cell growth and spread.
USP17L6P has also been shown to play a role in the regulation of T-cell development and function, which may be relevant to the regulation of neurodegenerative disorders.
Conclusion
In conclusion, USP17L6P is a gene that is part of the ubiquitin specific peptidase 17 like family and has the potential to serve as a drug target and biomarker for various diseases. Further research is needed to fully understand its role in the regulation of protein-protein interactions and its potential as a drug target and biomarker.
Protein Name: Ubiquitin Specific Peptidase 17 Like Family Member 6, Pseudogene
Functions: Deubiquitinating enzyme that removes conjugated ubiquitin from specific proteins to regulate different cellular processes that may include cell proliferation, progression through the cell cycle, cell migration, and the cellular response to viral infection. Seems to be non-functional in the regulation of apoptosis
The "USP17L6P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP17L6P comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
USP17L7 | USP17L8 | USP17L9P | USP18 | USP19 | USP2 | USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT | UXT-AS1 | VAC14 | Vacuolar H+ ATPase | VAMP1 | VAMP2 | VAMP3 | VAMP4 | VAMP5 | VAMP7 | VAMP8 | VANGL1 | VANGL2 | VAPA | VAPB | VARS1 | VARS2 | Vascular endothelial growth factor receptor (VEGFR) | Vascular endothelial growth factors (VEGF) | VASH1
